FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a bifunctional antibody coupled to the sequence of the iduronate-2-sulfatase enzyme via a glycine-serine junction, which has a high affinity for the human insulin receptor.
EFFECT: invention makes it possible to effectively treat mucopolysaccharidosis type II.
1 cl, 2 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| PRODUCTION OF ACTIVE HIGHLY PHOSPHORYLATED N-ACETYLGALACTOSAMINE-6-SULPHATASE AND USE THEREOF | 2011 |
|
RU2607376C2 |
| PRODUCING ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULPHATASE ENZYMES AND USE THEREOF | 2009 |
|
RU2510820C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| MODIFIED SULPHAMIDASE AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2708026C2 |
| VECTORS BASED ON ADENO-ASSOCIATED VIRUSES FOR TREATING MUCOPOLYSACCHARIDOSES | 2016 |
|
RU2744593C2 |
| MEDICAL AGENTS DELIVERY TO THE CENTRAL NERVOUS SYSTEM | 2011 |
|
RU2626514C2 |
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
